home / stock / slgl / slgl quote
Last: | $0.821 |
---|---|
Change Percent: | -1.75% |
Open: | $0.879 |
Close: | $0.821 |
High: | $0.879 |
Low: | $0.8146 |
Volume: | 7,634 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.821 | $0.879 | $0.821 | $0.879 | $0.8146 | 7,634 | 07-19-2024 |
$0.863858 | $0.82 | $0.863858 | $0.864999 | $0.82 | 33,231 | 07-18-2024 |
$0.86 | $0.841 | $0.86 | $0.9299 | $0.82 | 13,800 | 07-17-2024 |
$0.8627 | $0.8555 | $0.8627 | $0.8899 | $0.8463 | 24,256 | 07-16-2024 |
$0.882 | $0.9312 | $0.882 | $0.97 | $0.836 | 130,966 | 07-15-2024 |
$0.96 | $0.88 | $0.96 | $0.96 | $0.8213 | 154,860 | 07-12-2024 |
$0.8705 | $0.88 | $0.8705 | $0.88 | $0.844 | 11,197 | 07-11-2024 |
$0.8568 | $0.91905 | $0.8568 | $0.938 | $0.8568 | 13,302 | 07-10-2024 |
$0.93 | $0.826 | $0.93 | $0.96 | $0.8033 | 73,911 | 07-09-2024 |
$0.8447 | $0.853 | $0.8447 | $0.853 | $0.8002 | 8,022 | 07-08-2024 |
$0.8524 | $0.8184 | $0.8524 | $0.9036 | $0.8184 | 25,176 | 07-05-2024 |
$0.9 | $0.9093 | $0.9 | $0.9093 | $0.8729 | 13,452 | 07-04-2024 |
$0.9 | $0.9093 | $0.9 | $0.9093 | $0.872901 | 13,452 | 07-03-2024 |
$0.9193 | $0.87 | $0.9193 | $0.9197 | $0.87 | 19,035 | 07-02-2024 |
$0.86 | $0.9 | $0.86 | $0.929 | $0.86 | 26,262 | 07-01-2024 |
$0.89 | $0.891 | $0.89 | $0.93 | $0.87 | 109,171 | 06-28-2024 |
$0.8699 | $0.84 | $0.8699 | $0.9194 | $0.84 | 10,853 | 06-27-2024 |
$0.9197 | $0.9001 | $0.9197 | $0.92485 | $0.896 | 34,451 | 06-26-2024 |
$0.9 | $0.839 | $0.9 | $0.936937 | $0.8221 | 37,907 | 06-25-2024 |
$0.8349 | $0.8 | $0.8349 | $0.8697 | $0.8 | 5,921 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...